highly significantp <0.0001
The group treated with VP2.51 from day 1 after treatment with L-BMAA (L-BMAA + VP2.51 PT1) ( S3 Movie ) presented highly significant differences in the evolution of the neurological evaluation from the group treated only with L-BMAA (F = 89.34, p <0.0001) ( Fig 3 ).